Elsevier

Neuroscience Letters

Volume 396, Issue 3, 3 April 2006, Pages 187-191
Neuroscience Letters

Positive immunoreactivity for vesicular monoamine transporter 2 in Lewy bodies and Lewy neurites in substantia nigra

https://doi.org/10.1016/j.neulet.2005.11.068Get rights and content

Abstract

Vesicular monoamine transporter 2 (VMAT2) is responsible for packing dopamine into vesicles, and reduces the effects of neurotoxins by sequestering them into vesicles. In this report, we tested the hypothesis that VMAT2 is associated with Lewy body (LB) formation by immunohistochemical staining of midbrain and cortical sections of autopsied brains of patients with Parkinson's disease (PD) and diffuse Lewy body disease (DLBD) for VMAT2 using a polyclonal antibody against VMAT2. LBs in the substantia nigra (SN) of PD and DLBD were immunoreactive for VMAT2, especially in the peripheral zone. Previous electron microscopic studies also revealed the presence of numerous dense core vesicles around the LBs, suggesting that these vesicles are related to LB formation. Indeed, the presence of a few vesicle-linked proteins such as synaptophysin and chromogranin A in LBs has been reported. Together with the low expression of VMAT2 in the SN of PD, the involvement of VMAT2 in LBs of the SN suggests the association of this protein in the neurodegeneration of nigral neurons in PD.

Section snippets

Acknowledgements

This study was supported by the Japanese Ministry of Education, Culture, Sports, Science and Technology (Grant-in-Aid for Scientific Research 80218510, N.H.).

Cited by (21)

  • Alpha-synuclein modulates dopamine neurotransmission

    2017, Journal of Chemical Neuroanatomy
    Citation Excerpt :

    Following its synthesis, dopamine is stored in the synaptic vesicles via vesicular monoamine transporter 2 (VMAT2), a function that is thought to reduce the harmful oxidative properties of dopamine metabolites (Liu et al., 1994). The disruption of dopamine sequestration into the synaptic vesicles is thought to be one of the early events in degeneration of dopamine neurons (Miller et al., 1999; Gonzalez-Hernandez et al., 2004; Yamamoto et al., 2006; Henry et al., 1994). Disruption in the expression or activity of VMAT2 has shown to increase oxidative stress (Chen et al., 2008a).

  • Decreased vesicular monoamine transporter 2 (VMAT2) and dopamine transporter (DAT) function in knockout mice affects aging of dopaminergic systems

    2014, Neuropharmacology
    Citation Excerpt :

    In vitro and in vivo studies of cells with different expression of DAT and VMAT2 correlate with the relative vulnerabilities of these cell types in Parkinsonian-like neurodegeneration (Uhl, 1998; Uhl et al., 1994). Indeed, low VMAT2 gene expression and protein level have been found in the brains of Parkinson's disease patients (Harrington et al., 1996; Miller et al., 1999) and VMAT2 has been observed in Lewy bodies in the substantia nigra (Yamamoto et al., 2006). Region-specific differences in sensitivity to aging in VMAT2 +/− mice are consistent with evidence that age-related and neurodegenerative disorders often manifest damage to specific neuronal populations but less severe, more broadly distributed abnormalities in other cell groups.

  • From α-synuclein to synaptic dysfunctions: New insights into the pathophysiology of Parkinson's disease

    2012, Brain Research
    Citation Excerpt :

    Interestingly, some of the α-synuclein-positive axonal swellings observed in the striatum were also immunopositive for the vesicular monoamine transporter 2 (VMAT2), which mediates dopamine vesicular uptake, thus suggesting the occurrence of a collapse of synaptic vesicle transport at axonal level. Interestingly, VMAT2-immunoreactivity has been found to be present in LN in the substantia nigra of PD patients (Yamamoto et al., 2006), an observation which further support the hypothesis that pathological α-synuclein deposition likely underlie the onset of axonal/synaptic damage. Taken together, all these evidences support the idea that α-synuclein aggregation may be involved in the onset of the dopaminergic dysfunction.

  • Synuclein modulation of monoamine transporters

    2011, FEBS Letters
    Citation Excerpt :

    Release of synthesized neurotransmitter by monoaminergic neurons in the brain requires packaging of DA, NE, or 5-HT into vesicles by the vesicular monoamine transporter 2 (VMAT2). VMAT2 co-localizes with α-Syn in the Lewy bodies of PD [18], and overexpression of α-Syn can disrupt VMAT2 function in various contexts [1]. The influence of β-Syn and γ-Syn upon VMAT2 expression and activity are not known.

View all citing articles on Scopus
View full text